Inflammatory Bowel Disease: A Microbial Perspective

Inflammatory bowel disease — encompassing Crohn's disease and ulcerative colitis — represents one of the clearest examples of microbiome-immune dysregulation resulting in clinical pathology. The microbiome is not merely correlated with IBD; current evidence supports a causal role in disease initiation and perpetuation, and microbiome-directed therapies are becoming standard adjuncts to conventional treatment.

Core Microbial Findings in IBD

IBD is consistently associated with a 25-50% reduction in microbial diversity relative to healthy controls. Landmark work by Gevers et al. (Cell Host Microbe, 2014) in newly diagnosed pediatric Crohn's identified expansion of Enterobacteriaceae (E. coli, Klebsiella), Fusobacterium, and Ruminococcus gnavus, with depletion of Faecalibacterium prausnitzii — the single most reproducible microbiome finding in Crohn's disease.

Faecalibacterium prausnitzii and IBD

F. prausnitzii is the most abundant butyrate producer in the healthy colon, comprising 5-15% of total colonic bacteria. Its depletion in Crohn's correlates with disease activity, mucosal healing, and post-surgical recurrence risk. F. prausnitzii produces microbial anti-inflammatory molecule (MAM), which directly inhibits NF-κB activation and reduces IL-8 secretion. Its abundance is inversely correlated with CRP, fecal calprotectin, and endoscopic disease activity scores. See our dedicated article on F. prausnitzii.

Adhesive-Invasive E. coli in Crohn's

Adherent-invasive E. coli (AIEC) strains colonize ileal mucosa in Crohn's patients, surviving within macrophages and inducing TNF-α secretion. Their prevalence in Crohn's ileal mucosa (36%) versus controls (6%) suggests a pathogenic, not merely opportunistic, role. Strategies to displace AIEC — through bacteriophage therapy (investigational) and competitive exclusion — are active research areas.

Microbiome-Targeted Therapeutics

Fecal microbiota transplantation (FMT) has demonstrated proof-of-concept efficacy in ulcerative colitis, with a landmark Australian RCT (Paramsothy et al., Lancet, 2017) showing 32% remission with intensive FMT versus 9% placebo. Probiotic adjuncts — particularly VSL#3 in UC maintenance — complement biologics by addressing the microbial substrate that immune-targeting therapies cannot correct alone.

Related: Dysbiosis and Disease · Faecalibacterium prausnitzii · Gut-Immune Connection